Drug Type Small molecule drug |
Synonyms- |
Target |
Action antagonists, inhibitors |
Mechanism EGFR antagonists(Epidermal growth factor receptor erbB1 antagonists), TrxR inhibitors(Thioredoxin reductase inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
License Organization- |
Drug Highest PhasePreclinical |
First Approval Date- |
Regulation- |
Molecular FormulaC24H24AuClFN6O2P |
InChIKeyTVXSJXAKCZETHP-UHFFFAOYSA-N |
CAS Registry3038386-42-1 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Lung Cancer | Preclinical | China | 19 Feb 2025 |